Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 16/20 | 0.79 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.79 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.79 |
| ▸ | TACR1 | P25103 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | GNRHR | P30968 | 1/20 | 0.53 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350785 | 0.94 | NTSR1 (0.69) | NTSR1NTSR2SORT1TACR1OPRM1 | |
| SCHEMBL29716634 | 0.88 | NTSR2 (0.75) | NTSR1NTSR2SORT1TACR1OPRM1 | |
| SCHEMBL29817589 | 0.88 | NTSR1 (0.61) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL29367784 | 0.82 | NTSR2 (0.62) | NTSR1NTSR2SORT1TACR1OPRM1 | |
| SCHEMBL29535981 | 0.82 | TACR1 (0.78) | NTSR1NTSR2SORT1TACR1OPRM1 | |
| SCHEMBL29350118 | 0.82 | TACR1 (0.78) | NTSR1NTSR2SORT1TACR1OPRM1 | |
| SCHEMBL29543021 | 0.82 | TACR1 (0.78) | NTSR1NTSR2SORT1TACR1OPRM1 | |
| SCHEMBL29666167 | 0.82 | NTSR1 (0.66) | NTSR1NTSR2SORT1TACR1OPRM1 | |
| SCHEMBL29533422 | 0.81 | NTSR1 (0.78) | NTSR1NTSR2SORT1OPRM1OPRD1 | |
| SCHEMBL12524037 | 0.80 | NTSR1 (0.65) | NTSR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-20250019415-A1 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | MONASH UNIVERSITY (AU) | 2025-01-16 | — | — | US | disclosed |
| CN-111247163-B | Screening assays, modulators and modulators of progressive glycation end product Receptor (RAGE) activation | 莫纳施大学 | 2024-11-26 | — | — | CN | disclosed |
| US-12060408-B2 | Screening assays, modulators and modulation of activation of Receptor for Advanced Glycation End-products (RAGE) | MONASH UNIVERSITY (AU) | 2024-08-13 | — | — | US | disclosed |
| CN-115843253-A | Methods and compositions for treating inflammatory conditions associated with infectious diseases | 蒂莱克特生物制剂有限责任公司 | 2023-03-24 | — | — | CN | disclosed |
| US-11591366-B2 | Macrocyclic compounds and methods of preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-02-28 | — | — | US | disclosed |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| CN-107615062-B | Hydrogel particles with tunable optical properties and methods of using the same | 弹弓生物科学公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060408-B2 | Screening assays, modulators and modulation of activation of Receptor for Advanced Glycation End-products (RAGE) | AGER, GPR174, GRK2 | NTSR1 353/4885NTSR2 335/4885SORT1 2139/4885 |
| US-11591366-B2 | Macrocyclic compounds and methods of preventing or treating pain | COX15, ACHE, TRPV1 | NTSR1 463/4885NTSR2 200/4885SORT1 4512/4885 |
| US-20250019415-A1 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | AGER, GPR174, GRK2 | NTSR1 353/4885NTSR2 335/4885SORT1 2139/4885 |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | VIP, NTSR2, VIPR2 | NTSR1 5/4885NTSR2 2/4885SORT1 3892/4885 |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | NTSR1 5/4885NTSR2 2/4885SORT1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.